Semaglutide 2.4 mg Gets US Approval for Fatty Liver Disease With Fibrosis
Semaglutide 2.4 mg/week received accelerated US approval for MASH with significant fibrosis, based on trials showing improvements in steatosis, disease resolution, and fibrosis reduction.
Quick Facts
What This Study Found
Semaglutide 2.4 mg/week achieved significant improvements in hepatic steatosis, MASH resolution, and fibrosis reduction in phase 2 and 3 trials, leading to conditional US approval.
Key Numbers
Semaglutide 2.4 mg/week SC. Conditional accelerated approval for MASH with F2/F3 fibrosis. Phase 2-3 data show MASH resolution and fibrosis improvement. Consistent cardiovascular and renal benefits.
How They Did This
Focused review of phase 2 and 3 clinical trial data supporting the accelerated US approval of semaglutide 2.4 mg/week for MASH with fibrosis.
Why This Research Matters
MASH is the most common cause of liver transplantation and had no effective pharmacological treatment until now. Semaglutide's approval changes the treatment landscape for millions of patients with fatty liver disease.
The Bigger Picture
This approval marks the beginning of a new era in liver disease treatment, where metabolic drugs address the root causes of fatty liver disease rather than just managing complications.
What This Study Doesn't Tell Us
Conditional accelerated approval requires confirmatory trials. Long-term effects on cirrhosis prevention and liver cancer risk reduction are not yet established.
Questions This Raises
- ?Will semaglutide prevent progression to cirrhosis in long-term use?
- ?How will this approval affect clinical practice guidelines for MASH management?
Trust & Context
- Key Stat:
- First effective MASH drug Semaglutide 2.4 mg/week is among the first medications to receive US approval for metabolic liver disease with fibrosis
- Evidence Grade:
- Based on phase 2 and 3 clinical trials supporting FDA accelerated approval — strong evidence but confirmatory long-term trials are required.
- Study Age:
- Published in 2025, covering the most recent clinical trial data and regulatory approval.
- Original Title:
- Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
- Published In:
- Liver international : official journal of the International Association for the Study of the Liver, 45(11), e70407 (2025)
- Authors:
- Petta, Salvatore, Kim, KyeongJin, Targher, Giovanni(4), Romeo, Stefano, Sookoian, Silvia, Zheng, Ming-Hua, Aghemo, Alessio, Valenti, Luca
- Database ID:
- RPEP-13039
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can semaglutide treat fatty liver disease?
Yes, semaglutide 2.4 mg weekly has received accelerated US approval for MASH (the inflammatory form of fatty liver disease) with significant fibrosis. Clinical trials showed it can reduce liver fat, resolve liver inflammation, and improve fibrosis.
What is MASH?
MASH (metabolic dysfunction-associated steatohepatitis) is the new name for what was previously called NASH. It is the inflammatory form of fatty liver disease that can progress to cirrhosis, liver cancer, and liver failure if untreated.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13039APA
Petta, Salvatore; Kim, KyeongJin; Targher, Giovanni; Romeo, Stefano; Sookoian, Silvia; Zheng, Ming-Hua; Aghemo, Alessio; Valenti, Luca. (2025). Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.. Liver international : official journal of the International Association for the Study of the Liver, 45(11), e70407. https://doi.org/10.1111/liv.70407
MLA
Petta, Salvatore, et al. "Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.." Liver international : official journal of the International Association for the Study of the Liver, 2025. https://doi.org/10.1111/liv.70407
RethinkPeptides
RethinkPeptides Research Database. "Focus on Semaglutide 2.4 mg/week for the Treatment of Metabo..." RPEP-13039. Retrieved from https://rethinkpeptides.com/research/petta-2025-focus-on-semaglutide-24
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.